ABSTRACT Objectives: Although current therapies for acute promyelocytic leukemia (APL), such as all-trans retinoic acid and arsenic trioxide, usually result in remission, some patients relapse. Early recognition of relapse is critical for prompt intervention. In this study, we systematically reviewed morphologic, immunophenotypic, and cytogenetic findings in paired diagnostic and relapsed APL cases and describe and quantify the changes in blast morphology at relapse.
Methods: By electronic database search, we identified eight paired diagnostic and relapsed APL cases for which peripheral blood or bone marrow smears were available for review. For two cases, diagnostic material was available for relapse after hematopoietic cell transplantation.
Results: Neoplastic hypergranular or microgranular promyelocytes with indented or bivalve nuclei predominated at diagnosis in all patients. Most patients had undifferentiated blasts at relapse and/or hypergranular blast equivalents with round to oval nuclei. Classic acute promyelocytic leukemia cells with bivalve nuclei and bundles of cytoplasmic Auer rods were easily identifiable in fewer than half of cases at diagnosis and rare to absent in all relapsed cases.
Conclusions: Morphologic features of relapsed APL overlap with other types of acute myeloid leukemia, creating diagnostic challenges, especially if no history is available when relapsing patients seek treatment for care.
The availability of all-trans retinoic acid (ATRA) therapy for acute promyelocytic leukemia (APL) has increased the importance of a rapid presumptive morphologic diagnosis. 1 APL has a distinctive blast morphology that was described in the French-American-British (FAB) classification system and more recently in the 2008 World Health Organization (WHO) classification as the classic type (M3 in FAB, hypergranular in WHO) or the variant type (M3v in FAB, microgranular in WHO), both of which are associated with disseminated intravascular coagulation. 2 A presumptive diagnosis of APL based on clinical presentation and morphology can be confirmed by detecting a 15;17 translocation by conventional (G-banded) cytogenetic analysis or by demonstrating fusion of the PML (15q24.1) and RARA (17q21.2) genes by fluorescence in situ hybridization (FISH) or reverse-transcriptase polymerase chain reaction (variant translocations and gene fusions occur in a minority of cases). Some authors have stressed the importance of recognizing at initial diagnosis not only the characteristic blasts with reniform nuclei and multiple Auer rods that we refer to as classic acute promyelocytic leukemia (CAPL) cells but also variant blast morphology. [3] [4] [5] The discovery that ATRA in combination with arsenic trioxide (ATO) can produce durable remissions in relapsed APL has made early morphologic recognition of relapse important. 6, 7 In our clinical practice, we observed cases of relapsed APL with t(15;17) after ATRA therapy where the blast morphology is atypical, resembling other types of acute myeloid leukemia. A prior smaller study has reported a single case of APL at second relapse with undifferentiated blast morphology. 8 In this study, we systematically compare paired diagnostic and relapsed APL cases and present a larger case series to describe and quantify morphologic changes that can potentially cause diagnostic challenges.
Materials and Methods

Patients
The Human Subjects Committee of the University of Minnesota, Minneapolis, determined that this study was exempt from review under federal guidelines 45 CFR Part 46.101(b) Category #4 as a review of existing records. A natural language search of the University of Minnesota Medical Center (UMMC) CoPath electronic pathology laboratory data system was performed using the keywords acute promyelocytic leukemia. The timeframe of the search (January 1, 2003, to December 31, 2013) was chosen to increase the likelihood that data such as diagnostic slides and cytogenetic and/or molecular results would be available, that patients would have received ATRA therapy, and that relapses would be captured. During this time period, there were 47 morphologic diagnoses of APL either presenting at UMMC for diagnosis and treatment or seen in consultation for relapsed disease (with review of original diagnostic specimen). Forty-three (91.5%) of these patients were initially treated with ATRA-based therapy. Twenty-three (48.9%) of these patients relapsed between 9 and 53 months of complete remission (CR). For eight (17.0%) of these relapsed patients, diagnostic slides were available for central retrospective review; three were originally diagnosed and treated at the UMMC and five at referring institutions.
Morphologic Analysis
Wright-Giemsa-stained blood or bone marrow aspirate smears obtained at original diagnosis and at relapse were 
Results
Our cohort included five men and three women with a median age of 45.5 years at diagnosis (range, 18-59 years). Five patients had a leukocytosis; none had a leukopenia. All patients were moderately to markedly thrombocytopenic at presentation. The median time to relapse was 15.5 months (range, 11-30 months). Treatment details are outlined in Table 1 ; in summary, all patients received ATRA and chemotherapy at initial diagnosis. All eight achieved CR after postrelapse therapy; one subsequently relapsed again and died of complications of leukemia. Six (75%) of the eight patients underwent hematopoietic cell transplantation (auto-or allotransplant); two (33%) of these patients relapsed within 2 years of transplantation. The remaining four transplanted patients and one of the patients who declined transplantation remain in CR at this time.
All eight patients in this study had a morphologic diagnosis of APL with t(15;17) and/or PML-RARA gene fusion at initial diagnosis and at relapse Table 2 . Two (25%) patients had normal karyotypes at the time of morphologic diagnosis of relapse, with PML-RARA detected by FISH. Cytogenetic findings did not correlate with changes in blast morphology.
Abnormal promyelocytes with bivalve or reniform nuclei were the predominant neoplastic cell at original diagnosis in all patients; in contrast, for five (62.5%) of the eight patients, the predominant neoplastic cells at relapse showed round to oval nuclei Figure 1 . The CAPL cell with bundles of cytoplasmic Auer rods comprised 2% or less of neoplastic cells in the majority (75%) of cases at original diagnosis. CAPL cells were rare to absent in all cases at first relapse and posttransplant relapse Table 3 . Morphologic evolution to undifferentiated blasts at relapse did not correlate with either hypergranular or microgranular morphology at diagnosis: one case had hypergranular morphology at diagnosis and microgranular morphology at relapse, and another case had microgranular morphology at diagnosis and hypergranular morphology at relapse. For the two patients who relapsed a second time after transplantation, blasts with round to oval nuclei were the predominant cell type at the time of posttransplant relapse.
Flow cytometric immunophenotyping was performed in 75% of the diagnostic cases, in 75% of the cases at first relapse, and for both of the two cases that relapsed after transplant. There was no definitive correlation between antigen expression pattern and blast morphology or a correlation between evolution to CD34 expression at relapse and undifferentiated morphology of blasts at relapse Table 4 .
Discussion
In this retrospective study from one institution, we characterized blast morphology of paired diagnostic and relapsed cases from eight patients with a diagnosis of APL who received ATRA as part of initial therapy. Using morphologic criteria (nuclear outline, degree of granularity of the cytoplasm, and presence or absence of Auer rods) similar to those described by Sainty et al, 
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Round to oval nucleus Classic bivalve or reniform nucleus Figure 1 Nuclear morphology of neoplastic cells in acute promyelocytic leukemia at diagnosis and relapse after all-trans retinoic acid-based therapy and hematopoietic cell transplant.
we found that most cases of relapsed APL showed a predominance of blasts with round to oval nuclei, as opposed to the leukemic promyelocytes with bivalve, reniform, or irregular nuclei typically seen in APL at diagnosis. The five cases with significant blast morphologic dedifferentiation at relapse did not show consistent changes in immunophenotype or karyotype compared with that seen at the time of diagnosis.
As far as we are aware, this is first case series reporting the frequent change in blast morphology in relapsed APL, with only a single case report of undifferentiated blast morphology at a second relapse of APL. That case was associated with a change in the blast immunophenotype from minimal to moderate expression of CD34. 8 Although a prior retrospective review of relapsed APL cases described morphologic findings as stable at relapse, it is unclear if the morphologic criteria outlined by Sainty et al 5 were used to characterize blast morphology (as was performed in our study). 9 The present study confirms the finding of undifferentiated blast morphology in APL at first relapse and posttransplant relapse, with no consistent correlation between the less mature blast morphology and expression of CD34 by blasts. One of our cases (patient 2) did show a transition from hypergranular cytoplasm at diagnosis to microgranular cytoplasm at relapse, with corresponding change to expression of CD34 by the neoplastic cells Figure 2 ; we are unable to draw any specific conclusions from this single case. The relationship between undifferentiated blast morphology at relapse after ATRA therapy is unclear. Early studies of ATRA therapy suggested that ATRA-sensitive APL cells could be eliminated via terminal differentiation and apoptosis, thus resulting in ATRA-resistant subclones. 10 Further reports have suggested that continued ATRA selection pressure was not required for the emergence of resistant subclones. 11 More current research in murine models has demonstrated that ATRA alone is insufficient to eradicate leukemic stem cells that can persist through some forms of therapy. 1 It is possible that the more primitive blast morphology that we have observed at relapse post-ATRA and after relapse treatment with ATO and hematopoietic cell transplantation represents reemergence of APL stem cells. A multi-institution study that seeks to identify the incidence of undifferentiated blast morphology in relapsed APL might provide additional insight.
Conclusions
In conclusion, relapsed APL with t(15;17) after ATRA therapy can have unexpected atypical blast morphology, with a predominance of blasts showing round to oval nuclei. This can create diagnostic challenges for the pathologist, particularly when a patient seeks treatment from a new institution for therapy, as the blasts could be misinterpreted as a second de novo or therapy-related acute leukemia. It is important to be able to recognize this atypical morphology because specific therapy may be directed at relapsed APL, which differs from other subcategories of acute myeloid leukemia, and we emphasize the importance of cytogenetic and molecular confirmation of suspicious cases. Furthermore, it should be emphasized that the blast morphology that has traditionally been described as pathognomonic of APL-the so-called faggot cell that we propose calling a CAPL cell-can be rare to absent at both diagnosis and relapse of this potentially curable leukemia.
